Which of the following is a false statement regarding losartan: (AIIMS Nov 2010)
|B||Associated with negligible cough|
|C||It has a long acting active metabolite|
|D||It is a competitive angiotensin receptor|
a. Losartan is a non-peptide angiotensin II receptor antagonist with high affinity and selectivity for the AT1 receptor.
b. It is partially carboxylated in liver to an active metabolite known as E3174. E3174 is 10-30 times more potent than Losartan.
c. Plasma half-life of losartan is two hours but that of E3174 is 6-9 hours. Losartan is well-tolerated and does not appear to provoke cough and dysgeusia.
d. The drug has uricosuric activity. Therefore, it is best suited to patients with gout and hypertension.